Explore
← New search
Filters:
Peking University
✕
1
✕
pre- and post-treatment tumor tissue, egfr-mutant nsclc patients (n=12 analyzed)
✕
clear all
1 matching publication(s)
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
PMID 38897205 · Cell Rep Med · 2024
L1
72/100